Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Solana Beach, California, focusing on developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system. The company, which went public in 2015, is advancing treatments such as ART27.13 for cancer-associated anorexia and ART26.12 for potential use in cancer, pain, inflammation, and anxiety-related disorders.
Artelo Biosciences Inc (ARTL) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Artelo Biosciences Inc's actual EPS was -$0.75, beating the estimate of -$0.86 per share, resulting in a 13.15% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
